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Parameswaran N. Hari,1 Navneet S. Majhail,2,3 Mei-Jie Zhang,1 Anna Hassebroek,2
Fareeha Siddiqui,4 Karen Ballen,5 Asad Bashey,6 Jenny Bird,7 Cesar O. Freytes,8 John Gibson,9
Gregaory Hale,10 Leona Holmberg,11 Ram Kamble,12 Robert A. Kyle,13 HillardM. Lazarus,14
Charles F. LeMaistre,15 Fausto Loberiza,16 Angelo Maiolino,17 Philip L. McCarthy,18
Gustavo Milone,19 Nancy Omondi,20 Donna E. Reece,21 Matthew Seftel,22 Michael Trigg,23
David Vesole,24 Brendan Weiss,25 Peter Wiernik,26 Stephanie J. Lee,1 J. Douglas Rizzo,1
Paulette Mehta27Blacks are twice as likely to develop and die from multiple myeloma (MM), and are less likely to receive an
autologous hematopoietic-cell transplant (AHCT) for MM compared to Whites. The influence of race on
outcomes of AHCT for MM is not well described.We compared the probability of overall survival (OS), pro-
gression-free survival (PFS), disease progression, and nonrelapse mortality (NRM) among Black (N5 303)
and White (N5 1892) recipients of AHCT for MM, who were reported to the Center for International
Blood and Marrow Transplant Research (CIBMTR) from 1995 to 2005. The Black cohort was more likely
to be female, and had better Karnofsky performance scores, but lower hemoglobin and albumin levels at di-
agnosis. Black recipients were younger and more likely to be transplanted later in their disease course. Dis-
ease stage and treatment characteristics prior to AHCTwere similar between the 2 groups. Black andWhite
recipients had similar probabilities of 5-year OS (52% versus 47%, P5.19) and PFS (19% versus 21%, P5.64)
as well as cumulative incidences of disease progression (72% versus 72%, P5.97) and NRM (9% versus 8%,
P5.52). In multivariate analyses, race was not associated with any of these endpoints. Black recipients of
AHCT for MM have similar outcomes compared to Whites, suggesting that the reasons underlying lower
rates of AHCT in Blacks need to be studied further to ensure equal access to effective therapy.
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Multiple myeloma (MM) remains an incurable dis-
ease, although prognosis has improved in the past
decade [1,2]. It is the most common hematologic ma-
lignancy among Blacks, and is the only hematologic
malignancy that is more frequent in this racial group
compared with Whites. In the United States, MM
and its precursor disease monoclonal gammopathy of
undetermined significance (MGUS) are twice as com-
mon in Blacks (annual incidence of 14.4/100,000 in
men and 9.8/100,000 in women compared with 6.6/
100,000 in White men and 4.1/100,000 in White
women) [1,3-7]. Proposed factors to explain the
increased incidence among Blacks include socioeco-
nomic factors, greater exposure to hazardous materials,
genetic predisposition, greater degree of background
antigenic stimulation, and a greater prevalence of obe-
sity [8-10]. Mortality rates from MM in the United
States are twice as high for Blacks compared to Whites
(8.3/100,000 for men and 6.0/100,000 for women com-
pared to 4.3/100,000 and 2.8/100,000 for White men
and women, respectively) [11].
Socioeconomic factors that may have an impact on
access to cancer therapy and therapeutic choices in-
clude place of residence, distance from care centers, un-
employment, availability and quality of health
insurance, poor nutrition, exposure to infectious
agents, lower educational level, and annual income
[12,13]. Prior comparisons have drawn conflicting con-
clusions on treatment outcomes among Blacks com-
pared with White patients with MM. Savage et al.
[13,14] found that Black patients had shorter survival
times following similar therapy for MM. Presentation
at later stages of disease, socioeconomic factors, or dif-
ferential access to care were thought to explain this dis-
parity. Other investigators have suggested that these
disparities in outcomes are primarily because of biolog-
ical characteristics [15,16].
Randomized clinical trials support the use of autol-
ogous hematopoietic-cell transplant (AHCT) as a stan-
dard therapy for MM [17,18]. We have previously
shown that Blacks are less likely to receive AHCT for
MM compared with their age- and sex-matched White
counterparts [19]. In the current study, we compared
outcomes between Black and White patients receiving
AHCT for MM to determine if disparate post trans-
plant outcomes validate lower AHCT use in Blacks.PATIENTS AND METHODS
The Center for International Blood and Marrow
Transplant Research (CIBMTR) consists of a volun-
tary working group of more than 450 transplant
centers worldwide. Centers contribute detailed data
on consecutive allogeneic and autologous transplants
to a statistical center at either the Medical College ofWisconsin in Milwaukee or the National Marrow
Donor Program (NMDP) Coordinating Center in
Minneapolis. Subjects are followed longitudinally,
with yearly follow-up. Computerized checks for
errors, physicians’ review of submitted data, and on-
site audits of participating centers ensure data quality.
Observational studies conducted by the CIBMTR are
done with a waiver of informed consent and in compli-
ance with HIPAA regulations as determined by the
Institutional Review Board and the Privacy Officer of
the Medical College of Wisconsin.
Patients
The study included 2195 (303 Black and 1892
White) adult (aged $18 years) recipients of AHCT
for MM who were transplanted between January 1995
and June 2005 (Table 1). Only recipients of peripheral
blood (PB) AHCT were included in this study; patients
who had received planned tandem AHCT (N5 582)
were excluded. Centers obtained information about
patient race and then reported it to the CIBMTR.
Statistical Methods
Patient-, disease-, and treatment-related factors
were compared between the Black and White cohorts,
using a chi-square test for categorical and a Kruskal-
Wallis test for continuous variables. Outcomes analyzed
included nonrelapse mortality (NRM), relapse/pro-
gression, progression-free survival (PFS), and overall
survival (OS). NRM was defined as death occurring in
the absence of relapse or progression of MM following
AHCT. Relapse/progression was defined according to
standard criteria [20]. Chemotherapy sensitivity was de-
fined as achievement of a partial or complete response
(PR, CR) to pretransplant therapy. PFS was defined as
survival without disease progression or relapse. Patients
alive and with no evidence of disease progression or re-
lapse were censored at the time of last follow-up. The
survival interval variable was defined as time from the
date of transplant to the date of death or last contact
and summarized by a survival curve. Probabilities of
OS and PFS were calculated using the Kaplan-Meier es-
timator [21,22]. NRM and relapse/progression were
calculated using cumulative incidence estimates. The
log-rank test was used for univariate comparisons.
Multivariate Cox proportional hazards regression
was used to examine the outcomes between Black
and White patient cohorts and to identify risk factors
associated with outcomes [23]. A stepwise forward
selection multivariate model was built to identify
covariates that influenced outcomes. Any covariate
with a value of P \ .05 was considered significant.
The proportionality assumption for Cox regression
was tested by adding a time-dependent covariate for
each risk factor and each outcome. Tests indicated
that all variables met the proportional hazards
Table 1. Patient Characteristics
White Black
Variable N (%) N (%) P-value
Number of patients 1892 303
Age median (range), years 57 (27-80) 55 (27-74) <.001
Age group at transplant, years .002
<50 396 (21) 88 (29)
50-64 1111 (59) 172 (57)
$ 65 385 (20) 43 (14)
Male sex 1136 (60) 164 (54) .05
Karnofsky score pretransplant .005
$90 1153 (61) 210 (69)
Hypertension <.001
Yes 471 (25) 143 (47)
Diabetes <.001
Yes 169 (9) 50 (17)
Body Mass Index .01
Underweight/normal (<25) 557 (29) 67 (22)
Overweight (25-29.9) 741 (39) 120 (40)
Obese/morbidly obese ($30) 594 (31) 116 (38)
Disease related
Durie-Salmon stage at diagnosis .25
I 203 (11) 25 (8)
II 562 (30) 101 (33)
III 1127 (60) 177 (58)
Immunochemical subtype of myeloma .34
IgG 1003 (53) 173 (57)
IgA 359 (19) 45 (15)
Light chain 329 (17) 54 (18)
Others/unknown 125 (11) 16 (10)
Albumin level at diagnosis .05
>3.5 g/dL 732 (39) 101 (33)
Hemoglobin at diagnosis <10 g/dL <.001
<10 g/dL 552 (29) 135 (45)
Creatinine at diagnosis .09
>1.5 mg/dL 361 (19) 74 (24)
B-2 microglobulin level at diagnosis .83
$5.5 mg/L 195 (10) 31 (10)
Prior chemotherapy regimens .78
MP ± others 334 (18) 50 (17)
VAD ± others (not MP) 1104 (58) 182 (60)
Cy ± others 300 (16) 52 (17)
Corticosteroids ± others 154 (8) 19 (6)
Number of lines of chemotherapy§ .29
1 1125 (59) 167 (55)
2 536 (28) 99 (33)
>2 231 (12) 37 (12)
Sensitive to chemotherapy prior to transplant .83
Sensitive 1434 (76) 228 (75)
Disease status at time of transplant .67
Complete remission/partial remission 1396 (74) 231 (76)
Treatment related
Time from diagnosis to transplant median (range), months 8 (<1-249) 9 (2-217) <.001
Time from diagnosis to transplant <.001
<12 months 1364 (72) 190 (63)
$12 months 528 (28) 113 (37)
Conditioning regimen .7
Melphalan only 1417 (75) 223 (74)
Melphalan + TBI ± others 204 (11) 35 (12)
Bu-Cy ± others (not TBI, not melphalan) 271 (15) 45 (15)
Median follow-up of survivors, median (range) 61 (<1-145) 51 (<1-132)
MP indicates Melphalan + Prednisone; VAD, vincristine + dexamethasone + adriamycin; Cy, cyclophosphamide; Bu, busulfan; TBI, total body irradiation;
Eval, evaluable.
§ Excludes stem cell priming.
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(RR). Any risk factors found to be significant were ad-
justed in the final Cox model. The main effect tested
(ie, Black versus White) was included in all models.The variables considered in multivariate analyses are
summarized in Table 2. Analyses were performed us-
ing SAS software, version 9.1 (SAS Institute, Cary,
NC).
Table 2. Variables Tested in Multivariate Analysis
Main effect variable:
Race/ethnicity: White* versus Black
Patient-related variables:
Age: <50* versus 50-64 versus$ 65
Sex: Male* versus Female
Karnofsky performance status at transplant: <90% versus $90%* versus
missing
Body mass index: underweight/normal* versus overweight versus obese/
morbidly obese
Hypertension anytime prior to transplant: yes* versus no
Diabetes anytime prior to transplant: yes* versus no
History of smoking prior to transplant: yes* versus no
Creatinine >1.5 mg/dL versus #1.5* mg/dL at diagnosis
MM subtype: IgG versus IgA versus Light chain versus others/unknown
Disease-related variables:
Durie-Salmon stage at diagnosis: I* versus II versus III
Number of lines of chemotherapy: 1* versus 2 versus >2
Sensitivity to chemotherapy prior to transplant: sensitive* versus others
Disease status prior to transplant: complete remission/partial remission*
versus others (includes minimal response, no response, stable disease,
relapse/progressive disease and unknown)
Prior chemotherapy regimens: MP* versus VAD versus Cy ± others versus
Corticosteroids ± others
Transplant-related variables:
Time from diagnosis to transplant: <12 months* versus others
Conditioning regimen: melphalan only* versus melphalan + TBI ± others
versus Bu-Cy ± others (not TBI, not melphalan)
Purging: yes* versus no
Year of transplant: 1995-2001 versus 2002-2005*
MP indicates Melphalan + Prednisone; VAD, vincristine + dexametha-
sone + adriamycin; Cy, cyclophosphamide; Bu, busulfan; TBI, total
body irradiation.
*Reference group.
Figure 1. Cumulative incidence of nonrelapse mortality.
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Patient Characteristics
Table 1 shows the characteristics of all patients
evaluated. Median ages at AHCT were 55 years for
Black compared to 57 years for White patients
(P\ .001). The Black cohort had a higher proportion
of females and patients with Karnofsky performance
status scores (KPS) .90 (69% versus 61%, P5 .005).
Blacks were more likely to have comorbidities such
as hypertension (47% versus 25%, P\ .001), diabetes
mellitus (l7% versus 9%, P\ .001), and obesity (38%
versus 31%, P5 .01). No statistically significant dif-
ferences in disease stage or MM subtype were identi-
fied. Blacks were also more likely to have a lower
hemoglobin (Hb\10 g/dL in 45% versus 29%, P\
.001) at diagnosis. No significant differences in the
levels of serum creatinine, beta-2 microglobulin, cal-
cium, or marrow plasmacytosis were identified. The
cohorts did not differ with respect to the type and
number of prior therapies or sensitivity to therapies
applied before transplantation. Blacks were trans-
planted later in the disease course, with 37% receiving
AHCT a year or more from diagnosis versus 28% in
Whites (P\ .001). There were no significant differ-
ences in conditioning regimens used or the receipt of
a salvage second AHCT.NRM and Relapse/Progression
Figure 1 shows the cumulative incidence of NRM.
The cumulative incidence of NRM was similar in both
groups. At 1 year, it was 5% (95% confidence interval
[CI] 4%-6%) in Whites versus 3% (95% CI 2%-6%)
in Blacks. At 5 years, it was 8% (95% CI 7%-9%) ver-
sus 9% (95% CI 6%-14%) in Whites and Blacks, re-
spectively. In multivariate analysis (Table 3), race
was not associated with NRM. Factors associated
with an increased risk of NRM were age $65 years,
KPS\90, and AHCT prior to 2002.
Figure 2 shows cumulative incidence of relapse/
progression. The cumulative incidence of relapse/pro-
gression was similar in both groups. At 1 year, it was
27% (95% CI 25%-29%) in Whites versus 28% (95%
CI 23%-34%) in Blacks. At 5 years it was 72% (95%
CI 69%-74%) versus 72% (95% CI 65%-78%) in
Whites and Blacks, respectively. In multivariate analysis
(Table 3), race was not associated with disease relapse or
progression. Factors associated with an increased risk of
relapse included KPS score\90, Durie-Salmon stage
III at diagnosis, receipt of 3 or more lines of chemother-
apy before AHCT, lack of chemosensitive disease prior
to AHCT, AHCT $12 months from diagnosis, and
later year of AHCT.PFS and OS
Figure 3 shows the probability of PFS. The 1- and
5-year probabilities of PFS were similar in both groups.
At 1 year, it was 68% (95% CI 66%-70%) in Whites
versus 68% (95% CI 63%-74%) in Blacks. At 5 years,
it was 21% (95% CI 18%-23%) versus 19% (95% CI
14%-25%) in Whites and Blacks, respectively. In mul-
tivariate analysis (Table 4), race was not associated with
PFS.
Figure 4 shows the probability of OS after AHCT.
The 1- and 5-year survival rates were also similar be-
tween the 2 cohorts. At 1 year, it was 87% (95% CI
85%-88%) in Whites versus 90% (95% CI 87%-93%)
in Blacks. At 5 years, it was 47% (95% CI 44%-49%)
versus 52% (95% CI 45%-59%) in Whites and Blacks,
respectively. In multivariate analysis (Table 4), race was
not a significant predictor of survival.
Table 3. Multivariate Analysis for Relapse and Nonrelapse Mortality
Relapse Nonrelapse mortality
Variable N RR P-Value N RR P-Value
Race
White 1850 1.00 1850 1.00
Black 296 0.92 (0.78-1.08) P 5.28 296 1.16 (0.75-1.80) P 5.51
Patient age, years
<50 475 1.00 P < .001
50-64 1253 1.55 (1.01-2.39) P 5.05
$65 418 3.50 (2.17-5.65) P < .001
Karnofsky Score prior to conditioning
<90 815 1.00 815 1.00
$90 1331 0.88 (0.79-0.98) P 5.02 1331 0.72 (0.53-0.98) P 5.03
Durie-Salmon stage at diagnosis
I 222 1.00 P < .001 222 1.00 P 5.004
II 652 1.23 (1.00-1.51) P 5.05 652 0.61 (0.35-1.06) P 5.08
III 1272 1.54 (1.27-1.87) P < .001 1272 1.16 (0.71-1.88) P 5.56
Number of lines of chemotherapy‡
1 1256 1.00 P 5.001
2 628 1.12 (0.99-1.27) P 5.07
>2 262 1.39 (1.16-1.66) P < .001
Sensitivity to chemotherapy prior
to transplant
Other 522 1.00
Sensitive 1624 0.76 (0.67-0.85) P < .001
Time from diagnosis to transplant
<12 months 1519 1.00
$12 months 627 1.19 (1.04-1.35) P 5.009
Year of transplant
1995-2001 1331 1.00 1331 1.00
2002-2005 815 1.17 (1.04-1.31) P 5.008 815 0.56 (0.39-0.81) P 5.002
RR indicates relative risk.
‡Excludes stem cell priming.
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at AHCT (.50 years), KPS score\90, higher Durie-
Salmon stage, those who received 2 or more lines of
therapy prior to AHCT, AHCT$12 months from di-
agnosis, and chemotherapy resistant disease (Table 4).
OS was also lower in patients who underwent AHCT
prior to 2002.
The major cause of mortality in both cohorts was
relapse or progression of MM that accounted for
72% of all deaths.DISCUSSION
Our analysis establishes that Black and Whites
have very similar outcomes after AHCT for MM.Figure 2. Cumulative incidence of disease relapse and progression.These results concur with observations in other studies
of nontransplant therapy that the disparity in out-
comes for MM disappears when Blacks receive identi-
cal therapy [24].
Several investigators have shown that Blacks have
outcomes similar to Whites when given the same non-
transplant treatment for MM. Rohatgi et al. [25]
showed that Blacks were less likely to receive chemo-
therapy, but they responded with similar outcomes
when given similar nontransplant therapy for MM.
In the pretransplant era, Modiano et al. [26] retrospec-
tively evaluated the impact of race in the results of the
SWOG 8829 study of conventional chemotherapy for
MM. From 99 study sites in the United States, 116
Black and 467 White patients were shown to haveFigure 3. Probability of progression-free survival.
Table 4. Multivariate Analysis for Overall Survival and Progression-Free Survival
Overall Survival Progression-Free Survival
Variable N RR P-Value N RR P-Value
Race
White 1892 1.00 1850 1.00
Black 303 0.94 (0.78-1.13) P 5.50 296 0.94 (0.81-1.09) P 5.39
Patient age, years
<50 484 1.00 P < .0001 475 1.00 P 5.03
50-64 1283 1.26 (1.09-1.46) P 5.002 1253 1.12 (0.99-1.27) P 5.08
$65 428 1.52 (1.26-1.83) P < .0001 418 1.24 (1.06-1.46) P 5.007
Karnofsky Score prior to conditioning
<90 832 1.00 815 1.00
$90 1363 0.74 (0.66-0.83) P < .0001 1331 0.87 (0.79-0.97) P 5.009
Durie-Salmon stage at diagnosis
I 228 1.00 P < .0001 222 1.00 P < .0001
II 663 1.13 (0.89-1.44) P 5.32 652 1.12 (0.93-1.36) P 5.23
III 1304 1.67 (1.34-2.09) P < .0001 1272 1.49 (1.25-1.79) P < .0001
Number of lines of chemotherapy‡
1 1292 1.00 P < .0001 1256 1.00 P 5.0002
2 635 1.10 (0.96-1.27) P 5.17 628 1.13 (1.00-1.27) P 5.04
>2 268 1.66 (1.37-2.01) P < .0001 262 1.41 (1.19-1.67) P < .0001
Sensitivity to chemotherapy prior to transplant
Other 533 1.00 522 1.00
Sensitive 1662 0.82 (0.72-0.94) P 5.003 1624 0.76 (0.68-0.85) P < .0001
Time from diagnosis to transplant
<12 months 1554 1.00 1519 1.00
$12 months 641 1.16 (1.01-1.34) P 5.04 627 1.16 (1.03-1.31) P 5.01
RR indicates relative risk.
‡Excludes stem cell priming.
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tively). There were no differences by stage or MM sub-
type. A smaller study from the Department of Defense
equal access health care system, reported on the out-
comes of 36 Black and 55 White newly diagnosed pa-
tients receiving AHCT for MM and observed
comparable outcomes between the 2 groups [27]. In
their study, there were no differences in the stage, he-
moglobin, calcium, or creatinine levels, although
Blacks did have higher C-reactive protein (CRP) levels
and a trend for less skeletal involvement. The authors
recommended a larger retrospective study such as the
current one. Other single center analyses comparing
Black and White recipients of AHCT for MM have
drawn conflicting conclusions. Khaled et al. [28] ana-
lyzed 101 Black patients and concluded that they
were likely to relapse earlier after AHCT. Survival
was not compared in this study. Saraf et al. [24] in theirFigure 4. Probability of overall survival.comparative study that included 38 Black and 32
White AHCT recipients, found that Black patients
had more prolonged responses and greater event-free
survival (EFS).
Unfortunately, there is ample evidence that Blacks
are less likely to receive chemotherapy for MM as well
as AHCT. Rohatgi et al. [25] reviewed patterns of
chemotherapy use for patients with MM outside the
clinical trial setting. From a population-based retro-
spective cohort of 49,021 patients aged 65 years or
older with stage II or III MM, they found that only
52% received chemotherapy. Blacks were less likely to
receive chemotherapy compared to Whites (47.6%
versus 52.8%) despite evidence that use of chemother-
apy decreased all cause mortality, myeloma specific
mortality, and increased survival [25]. The reasons
for the disparate access are unclear, because control-
ling for socioeconomic status did not eliminate the dis-
parity in the receipt of chemotherapy.
These disparities in the receipt of therapy occur in
the transplant setting as well. Joshua et al. [19], in a
previous study from the CIBMTR, demonstrate that
Whites are more likely to receive AHCT for newly
diagnosed MM compared to an age- and sex-adjusted
Black population. Using data from the SEER and
CIBMTR registries, the study showed that age- and
sex-adjusted odds of receiving AHCT for MM is 1.72
times greater in Whites compared to Blacks. Although
our study cannot address the reasons for this underuti-
lization of AHCT in Blacks, interesting conclusions can
be drawn regarding AHCT for MM in Black patients.
Biol Blood Marrow Transplant 16:395-402, 2010 401Race and Outcomes of AHCT for MMIt has been proposed that reduced access to treat-
ment for MM may be related to actual or perceived
worse outcomes in Black patients. Our study clearly
shows that outcomes are not different between Blacks
and Whites receiving AHCT for MM, suggesting this
treatment modality should be offered to all patients
when medically appropriate. These results are in ac-
cordance with a meta-analysis of patients treated for
14 different cancers, where survival in the majority of
cancers was similar between races when comparable
treatment was given [29].
The pretransplant characteristics of Black recipi-
ents of AHCT are interesting. The Black cohort was
younger and had better performance status than the
White cohort, despite higher rates of anemia and other
comorbidities at diagnosis. These differences likely
indicate a selection bias operating against older Black
patients with lower KPS scores with regard to referral
for consideration of AHCT. Black patients were also
likely to have had a longer time between diagnosis
and transplantation compared to Whites, while receiv-
ing a similar number of chemotherapy regimens and
having similar responses. This suggests delayed refer-
ral for consideration of AHCT. A referral bias favoring
only the healthiest Black patients for transplant may be
in effect, whereas patients with less favorable clinical
features may only be offered nontransplant or even
nontreatment options.
The major strength of our study is the broad rep-
resentation of transplant centers making it very likely
that these results are applicable to the transplant com-
munity as a whole. In this analysis, we are unable to
draw any conclusions about factors associated with
nonreceipt of transplant in Blacks because a nontrans-
plant population is not represented. The characteris-
tics of the population of black MM patients not
receiving AHCT need to be analyzed to identify the
causes of a under utilization of AHCT. It is possible
that many Blacks who are not receiving stem cell trans-
plantation for myeloma are forgoing the transplant by
choice. However, it is also possible that referral bias,
unequal access to tertiary care, compliance gap, reluc-
tance to enter clinical trials, and socioeconomic dispar-
ities account for some of the differences in utilization
of AHCT for patients with MM. With the demonstra-
tion of equal outcomes for Blacks with MM, further
study and definitive action to ensure better awareness
and delivery of transplant options for the Black popu-
lation is warranted.ACKNOWLEDGMENTS
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